Aim: In radioiodine therapy (RIT) of benign thyroid-disorders empirical half-lives (HL emp)
may be used to calculate therapeutic dose. In this study the effective half-life (HLf as well as …

Version 4 of the guideline for radioiodine therapy for benign thyroid diseases includes an
interdisciplinary consensus on decision making for antithyroid drugs, surgical treatment and …

The version 5 of the guideline for radioiodine therapy of benign thyroid disorders is an
update of the version 4, which was published by the German Society of Nuclear Medicine …

Radioiodine (RAI) is becoming the preferred treating option for benign thyroid diseases.
Hyperthyroidism is defined as hypermetabolic state caused by high levels of circulating …

Purpose Radioiodine therapy (RIT) of benign thyroid diseases is an established therapy.
This study aimed to identify factors predictive for outcome in patients with non-toxic goiter …

The success rate of radioiodine (I-131) therapy for toxic goiter and solitary hyperfunctioning
nodules depends on thyroid volume, compensation of hyperthyroidism, timing of the …

This document provides the new EANM guideline on radioiodine therapy of benign thyroid
disease. Its aim is to guide nuclear medicine physicians, endocrinologists, and practitioners …

Aim: The impact of our dosimetry concept on radioiodine therapy success in Graves' disease
(GD) was analysed. Three questions arised: Did individual estimation of pretherapeutic …

Benign thyroid disorders, especially hyper-and hypothyroidism, are the most prevalent
endocrine disorders. The most common etiologies of hyperthyroidism are autoimmune …

Radioiodine therapy of benign thyroid diseases (focal=[toxic adenoma], multifocal,
disseminated autonomy, Grave's disease or clinical relevant goitre) needs to be and can be …